The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Subscribe To Our Newsletter & Stay Updated
